Once hMSCs lodge within the pulmonary microcirculation following intravenous administration, local reductions of CD40L could ameliorate endothelial dysfunction and possibly reduce inflammatory pulmonary edema. The gene discussed is CD40LG; the disease is endothelial dysfunction.